Acquired deficit of antithrombin and role of supplementation in septic patients during continuous veno-venous hemofiltration

ASAIO Journal

Volumn 54, Issue 1, 2008, Pages 124-128

  Lafargue, Mathieu ^a   Joannes Boyau, Olivier ^a   Honoré, Patrick M ^b   Gauche, Bernard ^c   Grand, Hubert ^c   Fleureau, Catherine ^a   Rozé, Hadrien ^a   Janvier, Gérard ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b Clinique Saint Pierre of Ottignies   (Belgium)

^c CHG R Boulin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; COAGULATION; COST EFFECTIVENESS; MEDICAL PROBLEMS;

ANTICOAGULATION; SEPTIC PATIENTS; UNFRACTIONATED HEPARIN (UHF);

PATIENT MONITORING;

ANTITHROMBIN; HEPARIN;

ACUTE DRUG ADMINISTRATION; ACUTE KIDNEY FAILURE; ADULT; AGED; ALBUMIN DIALYSIS; ARTICLE; BLOOD CLOTTING; BOLUS INJECTION; CELL SURVIVAL; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOCARDITIS; FRANCE; HEMOFILTRATION; HUMAN; MULTICENTER STUDY; PANCREATITIS; PERITONITIS; PNEUMONIA; PROSPECTIVE STUDY; PROTEIN DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; SUPPLEMENTATION; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; EQUIPMENT DESIGN; HEMOFILTRATION; HEPARIN; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; SEPSIS; TIME FACTORS;

EID: 38349161027     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e31815cc3bf     Document Type: Article

References (37)

1. Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 351: 159-169, 2004.
2. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477, 1993.
3. Metnitz PG, Krenn CG, Steltzer H, et al: Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 30: 2051-2058, 2002.
4. Journois D. SF: extra renal blood purification in intensive care: Masson collection; 2003.
5. Fourrier F, Jourdain M, Tournoys A: Clinical trial results with antithrombin III in sepsis. Crit Care Med 28: 38-43, 2000.
6. Brandt P, Jespersen J, Sorensen LH: Antithrombin-III and platelets in haemodialysis patients. Nephron 28: 1-3, 1981.
7. Despotis GJ, Levine V, Joist JH, et al: Antithrombin III during cardiac surgery: Effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 85: 498-506, 1997.
8. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 67: 2361-2367, 2005.
9. Ranucci M: Antithrombin III. Key factor in extracorporeal circulation. Minerva Anestesiol 68: 454-457, 2002.
10. Marciniak E, Gockerman JP: Heparin-induced decrease in circulating antithrombin-III. Lancet 2: 581-584, 1977.
11. Ranucci M, Isgro G, Cazzaniga A, et al: Different patterns of heparin resistance: therapeutic implications. Perfusion 17: 199-204, 2002.
12. Bone RC: Sepsis, the sepsis syndrome, multi-organ failure: A plea for comparable definitions. Ann Intern Med 114: 332-333, 1991.
13. Vincent JL, Abraham E, Annane D, et al: Reducing mortality in sepsis: New directions. Crit Care 6: 1-18, 2002.
14. Frank RD, Weber J, Dresbach H, et al: Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int 60: 1972-1981, 2001.
15. Li W, Johnson D, Esmon C, Huntington J: Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 11: 857-862, 2004.
16. Diehl JL, Borgel D: Sepsis and coagulation. Curr Opin Crit Care 11: 454-460, 2005.
17. Lemmer JH Jr, Despotis GJ: Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 123: 213-217, 2002.
18. Zaidan JR, Johnson S, Brynes R, et al: Rate of protamine administration: Its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 65: 377-380, 1986.
19. Toulon P, Jacquot C, Capron L, et al: Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Thromb Haemost 57: 263-268, 1987.
20. Salmon J, Cardigan R, Mackie I, et al: Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med 23: 38-43, 1997.
21. Bastien O, French P, Paulus S, et al: Antithrombin III deficiency during continuous venovenous hemodialysis. Contrib Nephrol 116:154-158, 1995.
22. Bastien O, Saroul C, French P, Belleville J: Ineffectiveness of heparin therapy caused by acquired antithrombin III deficiency in continuous hemodialysis. Presse Med 19: 85, 1990.
23. Shulman RI, Singer M, Rock J: Continuous renal replacement therapy. Keeping the circuit open: Lessons from the lab. Blood Purif 20: 275-281, 2002.
24. Eisele B, Lamy M, Thijs LG, et al: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24: 663-672, 1998.
25. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 286: 1869-1878, 2001.
26. Tan HK, Baldwin I, Bellomo R: Continuous veno-venous hemo-filtration without anticoagulation in high-risk patients. Intensive Care Med 26: 1652-1657, 2000.
27. Uchino S, Fealy N, Baldwin I, et al: Continuous venovenous hemofiltration without anticoagulation. ASAIO J 50: 76-80, 2004.
28. du Cheyron D, Bouchet B, Bruel C, et al: Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: A case-control study. Crit Care 10: R45, 2006.
29. Joannes-boyau O, Rapaport S, Fleureau C, et al: Antithrombin continuous hémofiltration in septic shock patients (Abstract), in SFAR, Paris, Congress, 2002.
30. Joannes-boyau O, Lafargue M, Honoré P, et al: Short filter lifespan during hemofiltration in sepsis: Antithrombin (AT) supplementation should be a good way to sort out this problem (Abstract 145). Blood Purif 23: 149-174, 2005.
31. Lu W, Mant T, Levy JH, Bailey JM: Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg 90: 531-534, 2000.
32. Schiffl H, Lang SM, Fischer R: Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 346: 305-310, 2002.
33. Ronco C, Bellomo R, Homel P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 356: 26-30, 2000.
34. Honore PM, Jamez J, Wauthier M, et al: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 28: 3581-87, 2000.
35. Joannes-Boyau O, Rapaport S, Bazin R, et al: Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock. ASAIO J 50: 102-109, 2004.
36. Cutts MW, Thomas AN, Kishen R: Transfusion requirements during continuous veno-venous haemofiltration: The importance of filter life. Intensive Care Med 2000, 26: 1694-1697, 2000.
37. Silvester W, Honoré P, Sieffert E, et al: Effects of heparin, prostacyclin or combination, and effects of polyacrylonitrile or polysulphone membranes on filter survival in critically ill patients on continuous veno-venous haemofiltration. Blood Purif 15: 124-125, 1997.